Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/EJE-07-0181
European Journal of Endocrinology, Vol 157, Issue 1, 1-8
Copyright © 2007 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cazabat, L.
Right arrow Articles by Raffin-Sanson, M.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cazabat, L.
Right arrow Articles by Raffin-Sanson, M.-L.

CLINICAL STUDY

Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas

Laure Cazabat1,2,3, Rossella Libè1,2,3,4, Karine Perlemoine1,2,3, Fernande René-Corail1,2,3, Nelly Burnichon3,5, Anne-Paule Gimenez-Roqueplo3,5, Laurence Dupasquier-Fediaevsky9, Xavier Bertagna1,2,3,6, Eric Clauser1,2,3, Philippe Chanson7,8, Jérôme Bertherat1,2,3,6 and Marie-Laure Raffin-Sanson1,2,3,9,10

1 INSERM, U567, 75 Paris, France, 2 Institut Cochin, Université Paris Descartes, CNRS (UMR8104), 75 Paris, France, 3 Faculté de Médecine René Descartes, Université Paris 5, Paris F-75014, France, 4 Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Unité d’Oncogénétique, 75 Paris, France, 5 Département de Génétique, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France, 6 Département d’Endocrinologie, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France, 7 Département d’Endocrinologie, Assistance Publique Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France, 8 Faculté de Médicine de Bicêtre, Université Paris Sud, 94 Le Kremlin Bicêtre, France, 9 Département d’Endocrinologie, Assistance Publique Hôpitaux de Paris, Hôpital Ambroise Paré, 92 Boulogne, France and 10 Faculté de Médecine Paris-Ile de France Ouest, Université de Versailles Saint-Quentin-en-Yvelines, 10 Garches, France

(Correspondence should be addressed to M-L Raffin-Sanson who is now at Unité d’Endocrinologie, Hôpital Ambroise Paré, 92240 Boulogne, France; Email: marie-laure.raffin-sanson{at}apr.aphp.fr)

Objective: Germline mutations of the aryl hydrocarbon receptor-interacting protein gene (AIP) have recently been described in three families with GH or prolactin-secreting tumors, as well as in a few patients with apparently sporadic somatotropinomas. The aim of the study was to determine the prevalence of AIP mutations in a large cohort of patients with apparently sporadic GH-secreting tumors.

Design: One hundred and fifty-four patients were included in a prospective cohort designed to study the genetic predisposition to GH-secreting tumors together with 270 controls.

Methods: In all these subjects, the entire coding sequence of the AIP gene was screened for germline mutations.

Results: AIP mutations were detected in 5 out of 154 patients (3%): nonsense mutations in exon 4 (p.Lys201X; n = 2) and in exon 6 (p.Arg304X), one deletion in exon 3 (c.404delA; pHis135LeufsX21), and one mutation affecting the splice acceptor site of exon 4 (c.469-2 A > G). The five patients with an AIP mutation were significantly younger (mean age ± S.D.: 25 ± 10 vs 43 ± 14 years, P = 0.005) and three of them presented with gigantism. One missense mutation (p.Arg304Gln) was found in a single patient that was absent in all controls.

Conclusions: Germline mutations of the AIP gene were found in a small proportion of patients with sporadic pituitary somatotropinomas. This study shows that age and gigantism are simple clinical features which can help to select patients for mutation screening. It also supports the role of AIP in pituitary tumorigenesis.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
M. Georgitsi, E. Heliovaara, R. Paschke, A. V. K. Kumar, M. Tischkowitz, O. Vierimaa, P. Salmela, T. Sane, E. De Menis, S. Cannavo, et al.
Large Genomic Deletions in AIP in Pituitary Adenoma Predisposition
J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 4146 - 4151.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Libe, A. Fratticci, J. Coste, F. Tissier, A. Horvath, B. Ragazzon, F. Rene-Corail, L. Groussin, X. Bertagna, M. L. Raffin-Sanson, et al.
Phosphodiesterase 11A (PDE11A) and Genetic Predisposition to Adrenocortical Tumors
Clin. Cancer Res., June 15, 2008; 14(12): 4016 - 4024.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. A. Leontiou, M. Gueorguiev, J. van der Spuy, R. Quinton, F. Lolli, S. Hassan, H. S. Chahal, S. C. Igreja, S. Jordan, J. Rowe, et al.
The Role of the Aryl Hydrocarbon Receptor-Interacting Protein Gene in Familial and Sporadic Pituitary Adenomas
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2390 - 2401.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
A. Beckers and A. F Daly
The clinical, pathological, and genetic features of familial isolated pituitary adenomas
Eur. J. Endocrinol., October 1, 2007; 157(4): 371 - 382.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 European Society of Endocrinology.